#12 - Lars Wilde: Scaling The Model For Psilocybin-Assisted Psychotherapy

Lars Wilde is the President, Chief Business Officer, and Co-founder of COMPASS Pathways. COMPASS is a UK life sciences company that works to expedite the approval and delivery of mental health therapies to patients and focuses primarily on testing psilocybin for use in patients with treatment-resistant depression (TRD).
Lars Wilde is the President, Chief Business Officer, and Co-founder of COMPASS Pathways. COMPASS is a UK life sciences company that works to expedite the approval and delivery of mental health therapies to patients and focuses primarily on testing psilocybin for use in patients with treatment-resistant depression (TRD). They have 22 trials running through the US and Europe for TRD.

In this conversation we speak about:
  • His personal journey and battles with anxiety, and seeking psychiatric help
  • The subjective experience of psilocybin and impact of emotional processing and cognitive function
  • Birth of COMPASS
  • The current landscape of the research
  • Models for therapies and how they can scale
  • Research questions that need to be addressed
  • COMPASS decision to patent psilocybin (and what this means for its scientific exploration)
  • Rescheduling psilocybin
Tommy Moore